The global Insulin Delivery Devices Market was valued at USD 30.9 billion in 2022 and is expected to grow significantly, ...

which are used to dispense insulin and other medications. Users of the devices in the UK will shortly be able to recycle empty pens at around 2,500 Boots, Lloyds, Rowlands, and various independent ...

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and ...

Insulin-aspart-szjj is the first rapid-acting insulin biosimilar approved and the third insulin product approved by the FDA.

The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...

According to the FDA, the medication quickly helps to lower mealtime blood sugar spikes to improve control of blood sugar in ...

First-ever rapid-acting insulin. This approval extends to a 3-milliliter single-patient-use prefilled pen and a 10-milliliter ...

Novo Nordisk has made its smart insulin pens available in the UK, giving people treated within the NHS for diabetes access to devices that can monitor and record dosing information for the first time.

Injectable Drug Delivery MarketThe global injectable drug delivery market is estimated to be valued at USD 49.44 billion in ...

Merilog is the third insulin biosimilar product approved by the FDA and joins the two long-acting insulin biosimilar products ...

NovoPen ®, the first insulin pen injector, was introduced in 1985. This article reviews the published evidence over two decades of use of the NovoPen ® family of injection devices in diabetes ...